Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor β
Background: Guanxin Danshen formulation (GXDSF) is a traditional Chinese herbal recipe recorded in the Chinese Pharmacopeia since 1995 edition, which consists of Salviae miltiorrhizae Radix et Rhizoma, Notoginseng Radix et Rhizoma and Dalbergiae odoriferae Lignum. Our previous research suggested GXD...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00777/full |
| _version_ | 1818453439467749376 |
|---|---|
| author | Xuehong Deng Xuehong Deng Xuehong Deng Xuehong Deng Xuehong Deng Xiaoyan Xing Xiaoyan Xing Xiaoyan Xing Xiaoyan Xing Xiaoyan Xing Guibo Sun Guibo Sun Guibo Sun Guibo Sun Guibo Sun Xudong Xu Haifeng Wu Guang Li Guang Li Guang Li Guang Li Guang Li Guang Li Xiaobo Sun Xiaobo Sun Xiaobo Sun Xiaobo Sun Xiaobo Sun |
| author_facet | Xuehong Deng Xuehong Deng Xuehong Deng Xuehong Deng Xuehong Deng Xiaoyan Xing Xiaoyan Xing Xiaoyan Xing Xiaoyan Xing Xiaoyan Xing Guibo Sun Guibo Sun Guibo Sun Guibo Sun Guibo Sun Xudong Xu Haifeng Wu Guang Li Guang Li Guang Li Guang Li Guang Li Guang Li Xiaobo Sun Xiaobo Sun Xiaobo Sun Xiaobo Sun Xiaobo Sun |
| author_sort | Xuehong Deng |
| collection | DOAJ |
| description | Background: Guanxin Danshen formulation (GXDSF) is a traditional Chinese herbal recipe recorded in the Chinese Pharmacopeia since 1995 edition, which consists of Salviae miltiorrhizae Radix et Rhizoma, Notoginseng Radix et Rhizoma and Dalbergiae odoriferae Lignum. Our previous research suggested GXDSF had positive effect on cardiovascular disease. Therefore, the aim of this study was to elucidate the effects of GXDSF on myocardial ischemia reperfusion injury-induced left ventricular remodelling (MIRI-LVR).Methods: The effects of GXDSF on cardiac function were detected by haemodynamics and echocardiograms. The effects of GXDSF on biochemical parameters (AST, LDH and CK-MB) were analyzed. Histopathologic examinations were performed to evaluate the effect of GXDSF on cardiac structure. In addition, the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to predict the main target of GXDSF. Target validation was conducted by using western blots and immunofluorescent double staining assays.Results: We found that +dp/dt and LVSP were significantly elevated in the GXDSF-treated groups compared with the MIRI-LVR model group. Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were increased in the GXDSF-treated groups compared with the model group. All biochemical parameters (AST, LDH and CK-MB) were considerably decreased in the GXDSF-treated groups compared with the model group. Fibrosis parameters (collagen I and III, α-SMA, and left ventricular fibrosis percentage) were decreased to different degrees in the GXDSF-treated groups compared with the model group, and the collagen III/I ratio was elevated by the same treatments. TCMSP database prediction and western blot results indicated that estrogen receptor β (ERβ) could be the main target of GXDSF. PHTPP, a selective antagonist of ERβ, could inhibit the expression of ERβ and the phosphorylation of PI3K and Akt in myocardial tissue induced by GXDSF, and partly normalize the improving effects of GXDSF on +dp/dt, LVEF, LVFS, LDH, CK-MB, α-SMA and myocardial fibrosis.Conclusion: Collectively, GXDSF showed therapeutic potential for use in the prevention and treatment of myocardial ischemia reperfusion injury-induced ventricular remodeling by upregulating ERβ via PI3K/Akt signaling. Moreover, these findings may be valuable in understand the mechanism of disease and provide a potential therapy of MIRI-IVR. |
| first_indexed | 2024-12-14T21:39:00Z |
| format | Article |
| id | doaj.art-be35a51ae6fe492780d69814db26c28a |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-14T21:39:00Z |
| publishDate | 2017-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-be35a51ae6fe492780d69814db26c28a2022-12-21T22:46:31ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122017-11-01810.3389/fphar.2017.00777252574Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor βXuehong Deng0Xuehong Deng1Xuehong Deng2Xuehong Deng3Xuehong Deng4Xiaoyan Xing5Xiaoyan Xing6Xiaoyan Xing7Xiaoyan Xing8Xiaoyan Xing9Guibo Sun10Guibo Sun11Guibo Sun12Guibo Sun13Guibo Sun14Xudong Xu15Haifeng Wu16Guang Li17Guang Li18Guang Li19Guang Li20Guang Li21Guang Li22Xiaobo Sun23Xiaobo Sun24Xiaobo Sun25Xiaobo Sun26Xiaobo Sun27Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaBeijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, ChinaKey Laboratory of Efficacy Evaluation of Chinese Medicine against Glycerolipid Metabolism Disorder Disease, State Administration of Traditional Chinese Medicine, Beijing, ChinaZhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, ChinaKey Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, ChinaInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaBeijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, ChinaKey Laboratory of Efficacy Evaluation of Chinese Medicine against Glycerolipid Metabolism Disorder Disease, State Administration of Traditional Chinese Medicine, Beijing, ChinaZhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, ChinaKey Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, ChinaInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaBeijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, ChinaKey Laboratory of Efficacy Evaluation of Chinese Medicine against Glycerolipid Metabolism Disorder Disease, State Administration of Traditional Chinese Medicine, Beijing, ChinaZhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, ChinaKey Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, ChinaInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaBeijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, ChinaKey Laboratory of Efficacy Evaluation of Chinese Medicine against Glycerolipid Metabolism Disorder Disease, State Administration of Traditional Chinese Medicine, Beijing, ChinaZhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, ChinaKey Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, ChinaYunnan Branch, Institute of Medicinal Plant, Chinese Academy of Medical Sciences and Peking Union Medical College, Jinghong, ChinaInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaBeijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, ChinaKey Laboratory of Efficacy Evaluation of Chinese Medicine against Glycerolipid Metabolism Disorder Disease, State Administration of Traditional Chinese Medicine, Beijing, ChinaZhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, ChinaKey Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, ChinaBackground: Guanxin Danshen formulation (GXDSF) is a traditional Chinese herbal recipe recorded in the Chinese Pharmacopeia since 1995 edition, which consists of Salviae miltiorrhizae Radix et Rhizoma, Notoginseng Radix et Rhizoma and Dalbergiae odoriferae Lignum. Our previous research suggested GXDSF had positive effect on cardiovascular disease. Therefore, the aim of this study was to elucidate the effects of GXDSF on myocardial ischemia reperfusion injury-induced left ventricular remodelling (MIRI-LVR).Methods: The effects of GXDSF on cardiac function were detected by haemodynamics and echocardiograms. The effects of GXDSF on biochemical parameters (AST, LDH and CK-MB) were analyzed. Histopathologic examinations were performed to evaluate the effect of GXDSF on cardiac structure. In addition, the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to predict the main target of GXDSF. Target validation was conducted by using western blots and immunofluorescent double staining assays.Results: We found that +dp/dt and LVSP were significantly elevated in the GXDSF-treated groups compared with the MIRI-LVR model group. Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were increased in the GXDSF-treated groups compared with the model group. All biochemical parameters (AST, LDH and CK-MB) were considerably decreased in the GXDSF-treated groups compared with the model group. Fibrosis parameters (collagen I and III, α-SMA, and left ventricular fibrosis percentage) were decreased to different degrees in the GXDSF-treated groups compared with the model group, and the collagen III/I ratio was elevated by the same treatments. TCMSP database prediction and western blot results indicated that estrogen receptor β (ERβ) could be the main target of GXDSF. PHTPP, a selective antagonist of ERβ, could inhibit the expression of ERβ and the phosphorylation of PI3K and Akt in myocardial tissue induced by GXDSF, and partly normalize the improving effects of GXDSF on +dp/dt, LVEF, LVFS, LDH, CK-MB, α-SMA and myocardial fibrosis.Conclusion: Collectively, GXDSF showed therapeutic potential for use in the prevention and treatment of myocardial ischemia reperfusion injury-induced ventricular remodeling by upregulating ERβ via PI3K/Akt signaling. Moreover, these findings may be valuable in understand the mechanism of disease and provide a potential therapy of MIRI-IVR.http://journal.frontiersin.org/article/10.3389/fphar.2017.00777/fullGuanxin Danshen formulamyocardial ischemia reperfusion injuryventricular remodelingnetwork pharmacologyestrogen receptor βPI3K/Akt |
| spellingShingle | Xuehong Deng Xuehong Deng Xuehong Deng Xuehong Deng Xuehong Deng Xiaoyan Xing Xiaoyan Xing Xiaoyan Xing Xiaoyan Xing Xiaoyan Xing Guibo Sun Guibo Sun Guibo Sun Guibo Sun Guibo Sun Xudong Xu Haifeng Wu Guang Li Guang Li Guang Li Guang Li Guang Li Guang Li Xiaobo Sun Xiaobo Sun Xiaobo Sun Xiaobo Sun Xiaobo Sun Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor β Frontiers in Pharmacology Guanxin Danshen formula myocardial ischemia reperfusion injury ventricular remodeling network pharmacology estrogen receptor β PI3K/Akt |
| title | Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor β |
| title_full | Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor β |
| title_fullStr | Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor β |
| title_full_unstemmed | Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor β |
| title_short | Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor β |
| title_sort | guanxin danshen formulation protects against myocardial ischemia reperfusion injury induced left ventricular remodeling by upregulating estrogen receptor β |
| topic | Guanxin Danshen formula myocardial ischemia reperfusion injury ventricular remodeling network pharmacology estrogen receptor β PI3K/Akt |
| url | http://journal.frontiersin.org/article/10.3389/fphar.2017.00777/full |
| work_keys_str_mv | AT xuehongdeng guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xuehongdeng guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xuehongdeng guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xuehongdeng guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xuehongdeng guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaoyanxing guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaoyanxing guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaoyanxing guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaoyanxing guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaoyanxing guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guibosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guibosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guibosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guibosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guibosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xudongxu guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT haifengwu guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guangli guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guangli guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guangli guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guangli guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guangli guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT guangli guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaobosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaobosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaobosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaobosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb AT xiaobosun guanxindanshenformulationprotectsagainstmyocardialischemiareperfusioninjuryinducedleftventricularremodelingbyupregulatingestrogenreceptorb |